Additional Information

This program was based on a multidisciplinary conference of leaders in renal cancer research and clinical care held on June 27-28, 2008. The program developed content for an educational proceedings summarizing recent progress and outlining priorities for research and clinical care.

The program was directed by Michael B Atkins, MD, Beth Israel Deaconess Medical Center/Dana Farber/Harvard Cancer Center. 

The proceedings of the meeting were published as a peer-reviewed supplement to the journal CANCER (Volume 115, Issue S10, Date: 15 May 2009), including a CME activity based on the consensus summary. Links to the table of contents, consensus summary statement, journal website (16 manuscripts and discussion from the meeting – no subscription required) and the CME activity are below.

The activity is no longer active.

Statement of Need
Recent progress in the treatment of patients with advanced renal cancer is impressive. There are now three potentially distinct targets and related therapeutic approaches available: VEGF +/- PDGF; mTOR and immunotherapy. However there is still considerable need for further advances in clinical research, disease assessment and treatment, and physician education. The purpose of this multidisciplinary program is to review, assess and summarize recent advances and recommendations to advance research and patient care, including: new ways biology is informing approaches to prognosis and therapy; recent advances in prognostic classification and their potential therapeutic impact; new data on approved and emerging therapies; and recommendations for future clinical research; and to summarize their findings to benefit other medical professionals who treat and care for renal cancer patients.

Educational Grant Support
Supported by educational grants provided by Genentech, Novartis Pharmaceuticals, Pfizer, Inc. and Wyeth Pharmaceuticals.

Sponsorship
CME sponsorship was proviced by InforMEDical Communications, Inc.